Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.30 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21238730 | 0.98 | GRIN1 (0.33) | GRIN1GRIN2AGRIN2B | |
| SCHEMBL21225681 | 0.93 | FKBP5 (0.36) | GRIN1GRIN2AFKBP5CRBN | |
| SCHEMBL1555859 | 0.93 | GRIN1 (0.32) | GRIN1GRIN2AGRIN2BOTUD7B | |
| SCHEMBL21225659 | 0.91 | FKBP5 (0.34) | GRIN1GRIN2AFKBP5CRBN | |
| SCHEMBL23009556 | 0.91 | FKBP5 (0.34) | GRIN1GRIN2AGRIN2BFKBP5CRBN | |
| SCHEMBL23009557 | 0.91 | FKBP5 (0.34) | GRIN1GRIN2AGRIN2BFKBP5CRBN | |
| SCHEMBL21225657 | 0.91 | FKBP5 (0.34) | GRIN1GRIN2AFKBP5CRBN | |
| SCHEMBL23009678 | 0.91 | FKBP5 (0.34) | GRIN1GRIN2AGRIN2BFKBP5CRBN | |
| SCHEMBL22975111 | 0.91 | FKBP5 (0.34) | GRIN1GRIN2AFKBP5CRBN | |
| SCHEMBL21225285 | 0.91 | FKBP5 (0.34) | GRIN1GRIN2AFKBP5CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312591-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2023-10-05 | — | — | US | disclosed |
| US-20230312591-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2023-10-05 | — | — | US | disclosed |
| CN-113603627-B | Synthesis method of pyrrolidone spiro-propane compound | 江西省科学院应用化学研究所 | 2023-08-18 | — | — | CN | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230131402-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-11530223-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20220220119-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2022-07-14 | — | — | US | disclosed |
| US-11299495-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2022-04-12 | — | — | US | disclosed |
| CN-113603627-A | Synthesis method of pyrrolidone spiro propane compound | 江西省科学院应用化学研究所 | 2021-11-05 | — | — | CN | disclosed |
| US-8604046-B2 | Substituted piperidine spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof | SANOFI (FR) | 2013-12-10 | — | — | US | disclosed |
| US-8604046-B2 | Substituted piperidine spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof | SANOFI (FR) | 2013-12-10 | — | — | US | disclosed |
| EP-2373652-B1 | SUBSTITUTED PIPERIDINE SPIRO PYRROLIDINONE AND PIPERIDINONES USED AS H3 MODULATORS | SANOFI SA (FR) | 2013-10-09 | — | — | EP | disclosed |
| US-20120258979-A1 | SUBSTITUTED PIPERIDINE SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-10-11 | — | — | US | disclosed |
| US-8227481-B2 | Substituted piperidine spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof | SANOFI (FR) | 2012-07-24 | — | — | US | disclosed |
| US-8227481-B2 | Substituted piperidine spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof | SANOFI (FR) | 2012-07-24 | — | — | US | disclosed |
| CN-102239168-A | Substituted piperidine spiro pyrrolidinone and piperidinones used as h3 modulators | SANOFI AVENTIS | 2011-11-09 | — | — | CN | disclosed |
| US-20110257213-A1 | SUBSTITUTED PIPERIDINE SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-10-20 | — | — | US | disclosed |
| EP-2373652-A1 | SUBSTITUTED PIPERIDINE SPIRO PYRROLIDINONE AND PIPERIDINONES USED AS H3 MODULATORS | SANOFI (FR) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010065803-A1 | SUBSTITUTED PIPERIDINE SPIRO PYRROLIDINONE AND PIPERIDINONES USED AS H3 MODULATORS | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299495-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | GRIN1 1/4885GRIN2A 2/4885GRIN2B 5/4885 |
| US-20110257213-A1 | SUBSTITUTED PIPERIDINE SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | HRH3, HRH4, PRLHR | GRIN1 18/4885GRIN2A 81/4885GRIN2B 154/4885 |
| US-11530223-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | GRIN1 1/4885GRIN2A 2/4885GRIN2B 5/4885 |
| US-20220220119-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | GRIN1 1/4885GRIN2A 2/4885GRIN2B 5/4885 |
| US-20120258979-A1 | SUBSTITUTED PIPERIDINE SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | HRH3, HRH4, PRLHR | GRIN1 18/4885GRIN2A 81/4885GRIN2B 154/4885 |
| US-20230131402-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | GRIN1 1/4885GRIN2A 2/4885GRIN2B 5/4885 |
| US-20230312591-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | GRIN1 1/4885GRIN2A 2/4885GRIN2B 5/4885 |
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | GRIN1 4507/4885GRIN2A 4676/4885GRIN2B 4555/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | GRIN1 4639/4885GRIN2A 4615/4885GRIN2B 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.